ArticleFrontiers in oncology2024

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.

Marcin Kubeczko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.